Chugai Pharmaceutical Co., Ltd. CHGCF

CHGCF Company Overview

Chugai Pharmaceutical Co., Ltd. is a Japan-based research-driven pharmaceutical company focused on the discovery, development, manufacturing, and commercialization of prescription medicines. The company operates primarily in the biotechnology and pharmaceutical industries, with a strong emphasis on oncology, immunology, hematology, and rare diseases. Chugai is widely recognized for its antibody engineering capabilities and for developing innovative biologic and small-molecule therapies. Its business model combines in-house research with strategic collaborations, most notably its long-standing alliance with Roche Holding AG, which holds a majority ownership stake in the company.

The company’s primary revenue drivers include oncology medicines, hemophilia therapies, and immunology products marketed in Japan and internationally. Major products have included treatments such as Actemra/RoActemra (tocilizumab), Hemlibra (emicizumab), Alecensa (alectinib), and Avastin. Chugai serves hospitals, specialty clinics, healthcare providers, and national healthcare systems, with Japan representing its core market while international revenue is supported through Roche-led commercialization agreements. Founded in 1925, Chugai evolved from a domestic pharmaceutical manufacturer into a globally recognized biotechnology innovator following its strategic alliance with Roche established in 2002.